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Introduction
Painful bone metastases are an important problem in oncology and
occur in 5075% of patients with breast and prostate cancer [1, 2].
Radionuclide treatment was introduced in the early 1940s [3,
4], but this mode of treatment has been more widely implement-
ed in the last two decades.
In recent years three trends could be seen in the development
of radionuclide treatment of bone metastases:
 a re-consideration of clinical indications for this treatment: there
is a shift from radionuclide palliation in patients with multiple, gener-
alised and painful bone metastases towards an early application of
this treatment in not very painful and not numerous metastases;
 a re-approach to the question of radiotoxicity, with particu-
lar emphasis on the question of myelotoxicity;
 an increasingly broader range of new radionuclides ap-
plied in this therapy, with a shift to short half-life and low-energy
isotopes; however, also a return to radioactive phosphorus-32 in
the treatment has recently been proposed.
Indications reconsidered
Early introduction of radionuclide treatment
Radionuclide treatment had been traditionally restricted to patients
with breast and prostate cancer, with multiple bone metastases and
severe pain. Today indications for radionuclide treatment apply also
to patients with a small number of metastases with little or no pain.
Therefore the expression bone pain palliation is increasingly more
often being replaced by the term treatment of bone metastases.
Radionuclide treatment of bone
metastases  current concepts
and  trends
Currently it is proposed that radionuclide therapy should be
used at an earlier stage of metastatic disease, when the analge-
sic effect is more intense and durable [5, 6]. This form of treat-
ment might be particularly beneficial in prostate cancer patients,
as survival from the beginning of bone pain is relatively long  3869
months [7]. It is recommended either to apply complimentary ex-
ternal radiotherapy, or to repeat radionuclide treatment. This can
lead to delaying opiate application and an improvement in ambu-
latory status and quality of life [5].
Moreover, the treatment of bone metastases is extended to
types of carcinoma other than breast and prostate.
Bone strengthening/tumoricidal effect
The second trend in radionuclide treatment is to focus on the me-
tastases localised in the places with a risk of pathologic fractures.
After radionuclide treatment a decrease in metabolic activity
in a large portion of metastases is seen [810]. In post-treatment
MRI studies, a major regression of bone metastases has been
shown, with almost total regression of those up to 20 mm and
with features of calcification in the bigger ones [9].
This is supported by in-vivo studies, where strontium-89, acting
as a calcium mimic, is incorporated into newly synthesised bone matrix
[11]. Other studies suggest weak tumoricidal effects of radionuclide
therapy, both in clinical studies [6, 12] and animal models [13]. It
may be hypothesised that both local tumoricidal effect and preven-
tion of pathological fractures may have a positive impact on improv-
ing the clinical outcome and survival shown by some studies [12].
Therefore, not only analgesic effect but also fracture preven-
tion seems to be a prospective aim of radionuclide therapy.
The myelotoxicity problem reconsidered
Bone marrow depression grade I and grade II occur in 1588%
of patients post radionuclide therapy, myelotoxicity of III and IV
grade in 38% of patients [5, 1418], depending on the radioiso-
tope used. The nadir of blood parameters may be expected
between the 3rd and 6th week after treatment, with subsequent
improvement, in cases of more radiotoxic isotopes, extended
to a few months.
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Evaluating bone marrow side effects of particular radioiso-
topes, a Relative Advantage Factor (RAF), assuming the effect of
the most toxic phosphorus-32 as 1.0, has been calculated for stron-
tium  89, rhenium  186, samarium  156, lutetium  177,
erbium  169, tin  117m and phosphorus  33 respectively as:
1.1, 1.5, 2.4, 3.2, 5.1, and 6.5 [19].
Repetitive radionuclide treatment does not increase myelo-
toxicity [20].
Is myelotoxicity life threatening? The myelotoxicity of thera-
peutic radionuclides is a fact to be remembered, the pre-treat-
ment haematological parameters have to be carefully evaluated
and in borderline cases the less myelotoxic therapeutic radioiso-
topes to be chosen. However, in the authors opinion this fact
should not be exaggerated. The fears of myelotoxicity have been
clearly pointed out by E.B. Silberstein [22], commenting on the
paper by Sciuto et al. [6]: to my knowledge the literature at-
tributes only 1 death from thrombocytopenia to 32P. No deaths
due to bone marrow depression were reported after the use of the
other radioisotopes. In practice, regarding the patients outcome,
none of the radioisotopes seems to be significantly more or less
toxic than any other in any published comparative trial [22, 23].
In the authors own experience, out of about 170 patients treated
in his department between 1999 and 2001, major bone marrow de-
pression, but still not requiring in-patient care, occurred in 3 cases
(unpublished data). Definitely, with prudent pre-treatment evaluation,
radionuclide treatment is a relatively safe modality, safer than external
sealed-sources therapy, particularly that of wide field of irradiation [24].
The choice of radioisotopes reconsidered
In the USA there is FDA approval for three radioisotopes for bone
metastases therapy: phosphorus-32, samarium-153 and stron-
tium-89. Phosphorus-32 can be omitted for its radiotoxicity, although
some authors advocate its return [16, 18, 21]. The remaining two
radioisotopes have both advantages and disadvantages.
Samarium-153 has a relatively fast analgesic effect, in about
two weeks or less, its myelotoxicity is lower, repetitive therapy may
be applied in a relatively shorter time, but the analgesic effect is
shorter when compared with strontium-89.
Strontium-89 has a longer-lasting analgesic effect, sometimes
even up to one year, but the start of this action is delayed, some-
times even up to one month or longer. Strontium-89 myelotoxicity
is higher and repetitive therapy can be applied not earlier than 34
months. Also, because of higher myelosensitivity in younger pa-
tients, radiotherapy with strontium is applied rather in older patients.
Therefore:
 if the aim is a fast analgesic effect in patients with strong
pain or if bone marrow shows depression due to previous radio-
or chemotherapy or/and in younger patients, the agent of choice
would be rather samarium-153;
 in older patients with lesser pain and with no myelodepres-
sion the choice would be either strontium-89 or combined therapy
with induction with samarium-153 continued with strontium-89.
Phosphorus-32 treatment  reconsidered?
It is proposed to return to bone metastases palliation with phos-
phorus-32 [16, 18, 21]. Phosphorus-32 has no good reputation,
perhaps due to the cases of leukaemia induction after its applica-
tion in the treatment of polycythemia. However, there are argu-
ments that P-32 myelotoxicity is seriously exaggerated [22]. In the
USA the costs of treatment with phosphorus-32 are roughly about
15% of the costs of treatment with strontium-89 or samarium-153
[21]. There are proposals to administer samarium-153 in early stag-
es of disease, with prognosed longer life span, and phosphorus-
32 in terminal patients. This argument may seem controversial,
but at least it is worthy of consideration.
Radioisotopes in trials
 the future of radionuclide therapy
A further guideline in bone radionuclide therapy is a shift towards
radionuclides with low-energetic radiation, therefore with a short
range in tissues and short half-life, thus with little bone marrow
toxicity [2529]. For example for phosphorus-33 the absorbed dose
in the bone marrow is 36-fold lower than for phosphorus-32 [29].
The characteristics of those radioisotopes as compared with phos-
phorus-32, strontium-89 and samarium-153 are given in Table 1.
Perhaps the solution for the next decade will be the genera-
tor-eluted radionuclides, such as rhenium-188; a radioisotope
chemically similar to technetium-99m and of a low production cost
[3032]. Rhenium-188, is an b-emitter with a half-life of 17 hours,
obtained in the decay of wolframium-188, a radioisotope with
a half-life of 69 days. Rhenium-188 is also applied in radioimmu-
notherapy and radionuclide brachytherapy. Rhenium-188 can be
administered either as Re-188-HEDP [31], or Re-188-(V)DMSA
 the latter agent targeting also medullary thyroid carcinoma and
other soft tissue tumours [30].
Conclusions
Nuclear medicine is gradually shifting towards therapeutic appli-
cations. Systemic radionuclide bone metastases therapy is a rel-
atively safe, successful and price-competitive modality when com-
pared with external sealed sources therapy. Whereas traditional
strontium-89 therapy remains a golden standard in therapy, it
seems that several business-rivals are replacing or are about to
replace this treatment modality.
Also, clinical indications for this kind of therapy are becoming
broader, which, as a piece of good news, is increasing the under-
standing between nuclear medicine specialists and oncologists.
Table 1. Physical parameters of chosen therapeutic radioisotpes
Radioisotope T ‰* (days) Mean energy Mean range in bone
** [keV] [mm]
Erbium-169 9.4 100 0.09
Lutetium-177 6.71 133 0.15
Phosphorus-32 14.3 695 1.7
Phosphorus-33 25.3 76 0.05
Samarium-153 1.9 225 0.32
Rhenium-186 3.8 323 0.64
Rhenium-188 0.7 220 0.11
Strontium-89 50.5 583 1.4
Tin-117m 13.6 135 0.15
*physical half-life;
**physical half-lives and mean energies taken from (Bishayee, 2000)
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